Reuters
31 May 2026, 12:03 UTC · 15w ago
Verdict
Headline takes no side. We score BONE −0.80 across two claims — strongly bearish.
−0.80strongly bearish
More negative than 89% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Akeso's experimental drug showed a 15% improvement in survival duration and a one-third reduction in death risk compared to BeOne Medicines' Tevimbra for advanced squamous non-small cell lung cancer.
More positive than 98% of claims this week
BeOne Medicines' immunotherapy Tevimbra was outperformed by Akeso's experimental drug in a comparative study.
So whatDirect evidence of inferiority against a competing drug threatens the commercial potential and valuation of the existing product.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 92% of claims this week
Which stocks this story touches
More negative than 89% of ticker scores this week
Its immunotherapy Tevimbra was outperformed by a competitor's drug in a clinical study.
More positive than 86% of ticker scores this week
Experimental drug showed superior efficacy and survival rates compared to a competitor's drug.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
2d ago
—
No price for BONE right now — the quote feed didn't answer.
BONE chart →
